Hepcidin is a small hormone, just 25 amino acids long, produced mainly by liver cells, and it acts as the body’s central iron gatekeeper. It controls how much iron enters the bloodstream from the food you digest, how much gets recycled from old red blood cells, and how much gets released from storage. When hepcidin levels rise, iron stays locked inside cells and out of circulation; when levels fall, iron flows freely. That single mechanism, scaled across the whole body, determines whether you end up with too much iron, too little, or just the right amount.
How Hepcidin Controls Iron Traffic
Your body has no dedicated way to excrete large amounts of iron. You lose small quantities through shed skin cells and intestinal lining, and through menstruation if you have periods, but there is no iron-dumping mechanism comparable to how the kidneys handle excess water or sodium. That means iron balance depends almost entirely on controlling how much iron enters the bloodstream in the first place. Hepcidin is the control switch.
The target of hepcidin is a protein called ferroportin, which sits on the surface of cells that export iron into the blood. These include the cells lining the upper intestine (where dietary iron is absorbed), macrophages (immune cells that recycle iron from worn-out red blood cells), and liver cells that store iron. When hepcidin binds to ferroportin, the transporter gets pulled inside the cell and broken down.1PubMed Central. Hepcidin-ferroportin axis in health and disease Without ferroportin on the cell surface, iron is trapped. The intestinal cell cannot hand off the iron it absorbed from your last meal. The macrophage cannot release the iron it just salvaged from a dead red blood cell. The net effect is that circulating iron drops.2PubMed Central. Iron metabolism and iron disorders revisited in the hepcidin era
When hepcidin levels fall, the opposite happens. Ferroportin stays on the cell surface, iron flows into the plasma, and the body absorbs more from the diet and recycles more from old cells. This on-off system is elegant in its simplicity, but the signals feeding into it are surprisingly complex.
What Tells the Liver to Make More or Less Hepcidin
Several signals converge on liver cells to dial hepcidin production up or down. The major ones are iron status, inflammation, the demand for new red blood cells, and oxygen levels.
When iron stores are high and transferrin (the blood’s iron-carrying protein) is well loaded, a signaling pathway in liver cells ramps up hepcidin production. This pathway relies on bone morphogenetic proteins, particularly BMP6, which activate specific signaling molecules inside the cell. Iron-loaded transferrin on its own cannot switch on this pathway, but it amplifies BMP6’s signal, making the liver more responsive when iron is abundant.3Journal of Clinical and Translational Hepatology. Serum Iron Overload Activates the SMAD Pathway and Hepcidin Expression of Hepatocytes via SMURF1 When iron is scarce, BMP6 drops and hepcidin production falls, opening the gates for more absorption.
Inflammation is the other powerful driver. The immune-signaling molecule interleukin-6, released during infections and chronic inflammatory conditions, directly activates hepcidin production through a different intracellular pathway.4PubMed Central. Interleukin-6 induces hepcidin expression through STAT3 This response is fast and strong, and it exists for a good evolutionary reason: by yanking iron out of circulation during an infection, the body starves invading bacteria and fungi of a nutrient they desperately need to grow.5PubMed. Hepcidin–a peptide hormone at the interface of innate immunity and iron metabolism Biologists call this strategy “nutritional immunity,” and it is one of the oldest antimicrobial defenses in vertebrates.
Working in the opposite direction, the bone marrow sends out a suppressive signal when it needs more iron to build red blood cells. Developing red blood cells produce a hormone called erythroferrone, which travels to the liver and tells hepatocytes to dial hepcidin down. This clears the way for more dietary iron absorption and more release from stores, feeding the marrow’s demand for hemoglobin production.6PubMed Central. Erythroferrone: An Erythroid Regulator of Hepcidin and Iron Metabolism Hypoxia, or low oxygen, also suppresses hepcidin. When tissues are oxygen-starved, hypoxia-responsive transcription factors reduce hepcidin gene activity, which again mobilizes more iron for red blood cell production.7Journal of Clinical Investigation. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
The interplay among these signals is what makes iron regulation both robust and vulnerable. In a healthy person, the system balances iron supply against demand with remarkable precision. But when one signal becomes abnormally dominant, the consequences can be severe.
When Hepcidin Is Too Low
If the body cannot produce enough hepcidin, iron absorption runs unchecked. Ferroportin stays active on intestinal and macrophage surfaces, and iron pours into the bloodstream far beyond what the body needs. Over years, this excess iron accumulates in the liver, heart, pancreas, and joints, eventually damaging tissues. This is essentially the story of hereditary hemochromatosis, the most common genetic iron overload disorder.
The classic form of hemochromatosis involves mutations in the HFE gene, which disrupt one of the signals that normally stimulates hepcidin production. A more severe and earlier-onset form, juvenile hemochromatosis, can result from mutations in the gene for hemojuvelin, a protein that helps activate the BMP signaling pathway in the liver. Mice lacking hemojuvelin show dramatic drops in hepcidin expression and develop serious iron overload.8PubMed Central. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload In the most extreme cases, patients with mutations directly in the hepcidin gene itself (HAMP) have undetectable hepcidin levels and develop organ damage at a young age.9PubMed Central. Hepcidin in iron overload disorders
Iron overload also develops in people with blood disorders like beta-thalassemia, even without hemochromatosis mutations. In thalassemia, the bone marrow is hyperactive but produces defective red blood cells, a state called ineffective erythropoiesis. The marrow floods the bloodstream with erythroferrone, which suppresses hepcidin and drives excessive iron absorption. Patients with thalassemia syndromes were found to have suppressed hepcidin regardless of their already-elevated iron stores, showing how powerfully the erythroid signal can override the iron-sensing pathway.9PubMed Central. Hepcidin in iron overload disorders Erythroferrone has been specifically implicated in driving this iron overload in thalassemia mouse models.10Blood. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia
When Hepcidin Is Too High
The mirror problem occurs when hepcidin is chronically elevated. Iron gets locked inside cells and never reaches the bloodstream, starving the bone marrow and causing anemia even when the body’s total iron stores are adequate. This is the hallmark of anemia of inflammation, sometimes called anemia of chronic disease. Conditions like rheumatoid arthritis, inflammatory bowel disease, chronic infections, and cancer keep interleukin-6 and other inflammatory signals elevated, which keeps hepcidin high, which keeps iron sequestered.11PubMed Central. Hepcidin and Iron in Health and Disease The irony of anemia of inflammation is that patients may have plenty of stored iron but functionally behave as if they are iron-deficient, because the iron cannot get out.
A rare genetic version of this same pattern exists. Mutations in the TMPRSS6 gene cause a condition known as iron-refractory iron deficiency anemia, or IRIDA. TMPRSS6 encodes a liver protease whose normal job is to chop up hemojuvelin, which reduces hepcidin signaling. Without functional TMPRSS6, hemojuvelin accumulates, hepcidin production runs unchecked, and ferroportin is constantly degraded.12PubMed Central. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia People with IRIDA have inappropriately high hepcidin for their iron status. In one family study, three of five affected patients had hepcidin levels above the upper normal limit despite being iron-deficient, a condition in which hepcidin should be nearly undetectable.13Haematologica. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron Oral iron supplements do not help these patients, because their gut cannot absorb the iron regardless of dose.
The Kidney Disease Connection
Chronic kidney disease creates a double hit on hepcidin. First, the ongoing inflammation common in kidney disease stimulates hepcidin production. Second, because hepcidin is a small peptide normally filtered and cleared by the kidneys, impaired kidney function means hepcidin accumulates in the blood instead of being removed.14PubMed Central. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease The elevated hepcidin blocks both dietary iron absorption and iron release from macrophages, producing functional iron deficiency and resistance to erythropoietin, the kidney hormone that normally stimulates red blood cell production.15Kidney International. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease
This helps explain why anemia in kidney disease is so stubborn to treat. Patients often receive erythropoietin injections and intravenous iron, yet still struggle with low hemoglobin. The hepcidin excess is part of why the standard therapies underperform. Interestingly, erythropoietin therapy itself can partially suppress hepcidin, likely because it stimulates erythroferrone release from the marrow, providing at least some counter-regulation.15Kidney International. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease
Hepcidin as a Diagnostic Tool
One of the most frustrating problems in clinical medicine is distinguishing true iron deficiency from the iron sequestration of chronic disease. Standard blood tests like serum ferritin and transferrin saturation are helpful but get muddied by inflammation: ferritin, for example, rises during inflammation regardless of iron stores. Measuring hepcidin directly could cut through this ambiguity, because hepcidin levels reflect the body’s integrated assessment of iron status and inflammatory signals.
Assays to measure hepcidin in blood have improved considerably. Both antibody-based methods and mass spectrometry approaches show good agreement with each other, which is an important step toward clinical standardization.16PubMed. Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients Research has shown that hepcidin levels correlate well with ferritin at lower levels and can help distinguish pure iron deficiency anemia from mixed presentations where inflammation is also involved.17PubMed. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders A reliable, easy-to-use hepcidin assay could be valuable for sorting out iron deficiency, functional iron deficiency in kidney disease, anemia of chronic disease, and iron overload conditions.18PubMed Central. A Novel Immunological Assay for Hepcidin Quantification in Human Serum
Despite this promise, hepcidin testing has not yet become a routine part of clinical practice. Reference ranges vary between methods, and there is no universally agreed-upon cutoff for clinical decision-making. Still, the trajectory is clear: as assays become more standardized, hepcidin measurement could eventually become as routine as checking ferritin or hemoglobin.
Therapies Targeting Hepcidin
Because hepcidin sits at the center of so many iron disorders, it has become an attractive drug target. Researchers are working on two broad strategies: raising hepcidin activity for diseases with too little, and blocking it for diseases with too much.
For iron overload conditions like thalassemia, the idea is to supply synthetic mini-versions of hepcidin that mimic its ferroportin-blocking action. In mouse models of beta-thalassemia, treatment with minihepcidins improved anemia, reduced the enlarged spleens characteristic of the disease, corrected ineffective red blood cell production, and brought down iron concentrations in the liver, spleen, and serum.19Haematologica. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major In one such model, minihepcidin treatment raised hemoglobin by nearly 3 g/dL and normalized liver iron to levels seen in healthy animals.20Blood. Treatment With Minihepcidin Peptide Improves Anemia and Iron Overload In a Mouse Model Of Thalassemia Intermedia These results suggest that restoring hepcidin activity could address both the anemia and the organ damage of thalassemia simultaneously, rather than treating them as separate problems.
For anemia of inflammation and similar conditions where hepcidin excess is the problem, the goal is to neutralize it. One approach uses Spiegelmers, mirror-image RNA molecules designed to bind and inactivate hepcidin in the bloodstream. In a primate model of inflammation-induced anemia, a hepcidin-neutralizing Spiegelmer completely blocked the drop in serum iron that normally follows an inflammatory challenge and prevented the decline in hemoglobin.21PubMed Central. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys Another approach uses fully human anti-hepcidin antibodies. In a mouse model of inflammatory anemia, such an antibody dramatically increased serum iron and raised hemoglobin, even without co-administration of erythropoietin. The antibody did not dampen the inflammatory response itself, confirming that neutralizing hepcidin alone was enough to restore iron availability.22Blood. Fully Human Anti-Hepcidin Antibodies Mobilize Iron and Treat Inflammatory Anemia in a Mouse Model
Most of these approaches are still in preclinical or early clinical stages. Translating results from mouse and primate models to human patients is always uncertain, but the consistent direction of the findings across different labs and models is encouraging.
Hepcidin and the Timing of Iron Supplements
One practical implication of hepcidin biology that has started reaching general audiences involves when you take iron supplements. Hepcidin follows a daily rhythm, running lower in the morning and climbing through the afternoon and evening, independent of meals. On top of that, a dose of oral iron itself triggers a hepcidin surge that suppresses absorption of the next dose. This creates a paradox: taking iron too frequently or in too-large doses can actually reduce how much you absorb, because each dose raises hepcidin and blocks the iron that follows.
This has led to clinical interest in morning dosing and alternate-day supplementation schedules. The logic is that if hepcidin is naturally lowest in the morning, a single morning dose gets absorbed before the daily rise in hepcidin, and skipping a day lets hepcidin fall back to baseline before the next dose. Research in iron-deficient pregnant mice has explored this timing question, with the rationale that pregnancy already suppresses hepcidin to enhance maternal iron absorption and placental transfer.23PubMed Central. Iron transport across the human placenta is regulated by hepcidin During pregnancy, hepcidin drops to facilitate both dietary absorption and iron delivery to the fetus through the placenta, but this suppression may not fully overcome the spike from supplemental iron if timing and dose are not optimized.
Why Athletes Should Care About Hepcidin
Endurance athletes, particularly runners, are prone to iron deficiency, and hepcidin may be part of the explanation. Prolonged exercise triggers a hepcidin spike roughly three hours after the workout ends. In a study of trained male and female runners, plasma hepcidin was about 50% higher three hours after a prolonged running bout compared to a rest day. Fractional iron absorption from a meal eaten after exercise was about 36% lower than after rest.24The Journal of Nutrition. A Prolonged Bout of Running Increases Hepcidin and Decreases Dietary Iron Absorption in Trained Female and Male Runners
The mechanism likely involves interleukin-6, which rises sharply during prolonged exercise and stimulates hepcidin through the same inflammatory pathway described earlier. For athletes who train daily or twice daily, this means their bodies may spend much of the day in a state of suppressed iron absorption. Combined with iron losses from foot-strike hemolysis, sweat, and gastrointestinal bleeding during intense exercise, the hepcidin spike creates a nutritional bottleneck. Some sports nutrition researchers now recommend that athletes who need iron supplements take them in the morning on rest days or at least several hours away from training sessions, to stay ahead of the post-exercise hepcidin rise.
Hepcidin and Nutritional Immunity
The inflammation-driven hepcidin surge is not a design flaw. It is an antimicrobial weapon that vertebrates have been refining for hundreds of millions of years. Nearly all pathogenic bacteria and fungi require iron to replicate. By pulling iron out of the bloodstream and locking it inside cells during an infection, hepcidin starves microbes of a nutrient they cannot synthesize on their own.5PubMed. Hepcidin–a peptide hormone at the interface of innate immunity and iron metabolism
This is also why iron supplementation during active infection is a delicate clinical question. Giving iron to someone whose body is deliberately withholding it can feed the pathogen. Large-scale supplementation trials in malaria-endemic regions have found that untargeted iron supplementation can increase the risk of severe infections in certain populations, likely because it undermines the hepcidin-mediated iron-withholding response. On the other hand, true iron deficiency itself impairs immune function. The clinical challenge is distinguishing “your body is hiding iron on purpose” from “your body genuinely does not have enough iron,” which circles back to the diagnostic potential of hepcidin measurement.
Some pathogens have evolved countermeasures. Certain bacteria secrete siderophores, small molecules that scavenge iron even at the vanishingly low concentrations the body maintains during infection. Others hijack host iron-transport proteins. The evolutionary arms race between host iron restriction and pathogen iron acquisition is one of the oldest and most intensively studied examples of coevolution in infectious disease biology, and hepcidin is the host’s primary battlefield weapon.